Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
Phase 3
Completed
- Conditions
- Hyperphosphatemia
- Interventions
- Registration Number
- NCT01187628
- Lead Sponsor
- Bayer
- Brief Summary
The objective of this study is to investigate the safety and the effect on reduction of serum phosphate of long-term administration of lanthanum carbonate (BAY77-1931) 750 to 2250 mg in patients with hyperphosphatemia who completed the 8 week double-blind treatment period of Study 14817 and are judged to be eligible for the long-term extension study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 123
Inclusion Criteria
- Patients who have completed the 8-week double-blind treatment period of Study 14817 and are judged to be eligible for the long-term extension study by the investigator (including those who plan to be on dialysis during the long-term extension study).
Read More
Exclusion Criteria
- Patients with any other conditions that the investigator defines as not appropriate to be enrolled in the study
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Arm 1 Fosrenol (Lanthanum Carbonate, BAY77-1931) -
- Primary Outcome Measures
Name Time Method Incidence of treatment emergent adverse events baseline to Week 60
- Secondary Outcome Measures
Name Time Method